Here's Why Ocugen Stock Skyrocketed Today
Shares of Ocugen (NASDAQ: OCGN) soared 43% on Thursday following positive clinical trial results and bullish analyst commentary.
Roth Capital analyst Zegbeh Jallah reiterated his buy rating and $10 price forecast for Ocugen's stock on Wednesday after its development partner, Bharat Biotech, shared positive data from an interim analysis of a phase 3 study of Covaxin, an investigational coronavirus vaccine.
Ocugen's stock price rose sharply on Thursday. Image source: Getty Images.
Source Fool.com
